Insider trades
Stock that executives, directors and 10% owners bought and sold on the open market, from the Form 4s they file with the SEC within two business days. Grants, option exercises and shares sold to cover taxes are left out.
- $1.5B bought by 343 insiders at 210 companies
- $3.2B sold by 267 insiders outside a trading plan
- $7.9B sold by 827 insiders under 10b5-1 plans
- 10 companies where two or more insiders bought (30 days)
Biggest buys
Past month, each insider's filings added up.
-
LENLennarBerkshire Hathaway Inc.10% owner, +1 joint filer$383M
-
CRBGCorebridge FinancialLife Insurance Co Nippon10% owner$225M
-
KODKodiak SciencesBaker Bros. Advisors LPDirector, +5 joint filers$157M
-
SAFXXCF GlobalEEME Energy SPV I, LLC10% owner$142M
-
GPIGroup 1 AutomotiveConifer Management, L.L.C.10% owner$97.8M
-
UUUUniversal Safety ProductsMilton C Ault IIIDirector$92.5M
-
GMEGameStopRyan CohenCEO$50.4M
-
BORRBorr DrillingTor Olav TroimDirector$43M
-
PAMPampa EnergiaMarcos Marcelo MindlinDirector$35.1M
-
GGRGogoroChung-Yao YinDirector$35.1M
Biggest sales
Past month, each insider's filings added up. Planned sales are marked.
-
IHTInnSuites Hospitality TrustJames F WirthCEO$4.2B
-
MDLNMedlineGIC Private Ltd10% owner, +2 joint filers$996M
-
ESTCElasticSteven SchuurmanDirector$323M
-
TALOTalos EnergyEmpresarial De Capitales S.a. De C.v. Control10% owner$253M
-
AVGOBroadcomHenry SamueliDirector$250M
-
THTarget HospitalityTDR Capital II Investments LP10% owner, +9 joint filers$202M
-
ANETArista NetworksJayshree UllalCEO$166M
-
KNTKKinetikISQ Global Fund II GP LLC10% owner, +4 joint filers$134M
-
CRWDCrowdStrikeBurt W. PodbereCFO$125M
-
NBISNebius GroupOphir NaveCOO$118M
Cluster buying
Companies where two or more insiders bought on the open market in the last 30 days, most buyers first
-
Che-Chia Wei CEO, Yuh-Jier Mii COO, Yung-Pei Chin COO, Yung-Chin Hou COO, +15 more
-
Reuben S Leibowitz Director, Larry C Glasscock Director, Daniel C. Smith Director, Gary M Rodkin Director, +7 more
-
R Jeffrey Bailly Director, Daniel L Florness Director, Srilata Zaheer Director, Charles T Lauber Director, +5 more
-
Steven M Paul Director, John Maraganore Director, Troy A. Ignelzi CFO, Wendy B. Young Director, +1 more
-
Thomas Jon Hammond Director, Sandip I Patel CFO, John Martin Schaible Chair, David Craig Ridenhour President, +1 more
-
John B Williamson III Director, Robert B Johnston Director, Paul W Nester CEO, Lawrence T. Oliver Senior VP and Secretary, +1 more
-
Michael Jordan Osborn CEO, John Walter Hazlett CFO, Gregory William Voorhies Director, James W Bernau President, +1 more
-
Matthew G De Soto Director, Albert J. Evans Director, Kimberly J Brumbaugh Director, Theodore W Mowery Director, +1 more
-
Smriti Laxman Popenoe CEO, Byron L Boston CEO, Terrence John Connelly Jr. Chief Investment Officer, Michael Andrew Sartori CFO
-
Lewis H Titterton Jr. Director, Amit Kumar CEO, Michael Catelani CFO, Arnold M Baskies Director
PCSA insider trades
Every open-market buy and sale in PCSA, one row per filing, newest first
-
Wendy Guy Chief Administrative OfficerPCSAProcessa PharmaceuticalsBuy$4,701 2,436 shares at $1.93 +20% to stakeTraded Jun 30 Filed Jul 1
-
Patrick Lin Chief Business - Strategy OffPCSAProcessa PharmaceuticalsBuy$4,065 2,106 shares at $1.93 +19% to stakeTraded Jun 30 Filed Jul 1
-
George K Ng CEOPCSAProcessa PharmaceuticalsBuy$5,900 3,057 shares at $1.93 +25% to stakeTraded Jul 1 Filed Jul 1
-
Russell Skibsted CFOPCSAProcessa PharmaceuticalsBuy$6,325 3,277 shares at $1.93 +24% to stakeTraded Jun 30 Filed Jul 1
-
David Young Pres. Research & DevelopmentPCSAProcessa PharmaceuticalsBuy$4,885 2,531 shares at $1.93 +13% to stakeTraded Jun 30 Filed Jul 1
-
David Young Pres. Research & DevelopmentPCSAProcessa PharmaceuticalsBuy$4,589 2,067 shares at $2.22 +12% to stakeTraded Jun 15 Filed Jun 16
-
Russell Skibsted CFOPCSAProcessa PharmaceuticalsBuy$5,892 2,654 shares at $2.22 +25% to stakeTraded Jun 15 Filed Jun 16
-
George K Ng CEOPCSAProcessa PharmaceuticalsBuy$5,472 2,465 shares at $2.22 +25% to stakeTraded Jun 15 Filed Jun 16
-
Patrick Lin Chief Business - Strategy OffPCSAProcessa PharmaceuticalsBuy$4,065 1,831 shares at $2.22 +20% to stakeTraded Jun 15 Filed Jun 16
-
Wendy Guy Chief Administrative OfficerPCSAProcessa PharmaceuticalsBuy$4,702 2,118 shares at $2.22 +22% to stakeTraded Jun 15 Filed Jun 16
-
David Young Pres. Research & DevelopmentPCSAProcessa PharmaceuticalsBuy$4,590 1,786 shares at $2.57 +12% to stakeTraded May 29 Filed Jun 1
-
Russell Skibsted CFOPCSAProcessa PharmaceuticalsBuy$5,890 2,292 shares at $2.57 +27% to stakeTraded May 29 Filed Jun 1
-
George K Ng CEOPCSAProcessa PharmaceuticalsBuy$5,472 2,129 shares at $2.57 +27% to stakeTraded May 29 Filed Jun 1
-
Patrick Lin Chief Business - Strategy OffPCSAProcessa PharmaceuticalsBuy$4,066 1,582 shares at $2.57 +21% to stakeTraded May 29 Filed Jun 1
-
Wendy Guy Chief Administrative OfficerPCSAProcessa PharmaceuticalsBuy$4,701 1,829 shares at $2.57 +23% to stakeTraded May 29 Filed Jun 1
-
George K Ng CEOPCSAProcessa PharmaceuticalsBuy$5,474 1,843 shares at $2.97 +31% to stakeTraded May 15 Filed May 19
-
David Young Pres. Research & DevelopmentPCSAProcessa PharmaceuticalsBuy$4,589 1,545 shares at $2.97 +11% to stakeTraded May 15 Filed May 19
-
Patrick Lin Chief Business - Strategy OffPCSAProcessa PharmaceuticalsBuy$4,066 1,369 shares at $2.97 +22% to stakeTraded May 15 Filed May 19
-
Wendy Guy Chief Administrative OfficerPCSAProcessa PharmaceuticalsBuy$4,702 1,583 shares at $2.97 +25% to stakeTraded May 15 Filed May 19
-
Russell Skibsted CFOPCSAProcessa PharmaceuticalsBuy$5,892 1,984 shares at $2.97 +31% to stakeTraded May 15 Filed May 19
-
George K Ng CEOPCSAProcessa PharmaceuticalsBuy$5,474 1,843 shares at $2.97 +86% to stakeTraded Apr 15 Filed May 19
-
Sian Bigora Chief Development OfficerPCSAProcessa PharmaceuticalsBuy$5,341 1,971 shares at $2.71 +36% to stakeTraded Apr 30 Filed May 19
-
David Young Pres. Research & DevelopmentPCSAProcessa PharmaceuticalsBuy$4,589 1,706 shares at $2.69 +14% to stakeTraded Apr 30 Filed May 1
-
Russell Skibsted CFOPCSAProcessa PharmaceuticalsBuy$5,891 2,190 shares at $2.69 +51% to stakeTraded Apr 30 Filed May 1
-
George K Ng CEOPCSAProcessa PharmaceuticalsBuy$5,471 2,034 shares at $2.69 +51% to stakeTraded Apr 30 Filed May 1
-
Patrick Lin Chief Business - Strategy OffPCSAProcessa PharmaceuticalsBuy$4,065 1,511 shares at $2.69 +32% to stakeTraded Apr 30 Filed May 1
-
Wendy Guy Chief Administrative OfficerPCSAProcessa PharmaceuticalsBuy$4,702 1,748 shares at $2.69 +37% to stakeTraded Apr 30 Filed May 1
-
George K Ng CEOPCSAProcessa PharmaceuticalsBuy$5,415 2,136 shares at $2.54 New stakeTraded Mar 31 Filed Apr 30
-
David Young Pres. Research & DevelopmentPCSAProcessa PharmaceuticalsBuy$4,589 1,545 shares at $2.97 +15% to stakeTraded Apr 15 Filed Apr 17
-
Patrick Lin Chief Business - Strategy OffPCSAProcessa PharmaceuticalsBuy$4,066 1,369 shares at $2.97 +41% to stakeTraded Apr 15 Filed Apr 17
-
Wendy Guy Chief Administrative OfficerPCSAProcessa PharmaceuticalsBuy$4,702 1,583 shares at $2.97 +51% to stakeTraded Apr 15 Filed Apr 17
-
Sian Bigora Chief Development OfficerPCSAProcessa PharmaceuticalsBuy$5,343 1,799 shares at $2.97 +49% to stakeTraded Apr 15 Filed Apr 17
-
Russell Skibsted CFOPCSAProcessa PharmaceuticalsBuy$5,892 1,984 shares at $2.97 +85% to stakeTraded Apr 15 Filed Apr 17
-
James R Neal DirectorPCSAProcessa PharmaceuticalsBuy$2,000 789 shares at $2.54 +2721% to stakeTraded Mar 31 Filed Apr 2
-
David Young Pres. Research & DevelopmentPCSAProcessa PharmaceuticalsBuy$4,588 1,810 shares at $2.54 +21% to stakeTraded Mar 31 Filed Apr 1
-
Russell Skibsted CFOPCSAProcessa PharmaceuticalsBuy$5,891 2,324 shares at $2.54 New stakeTraded Mar 31 Filed Apr 1
-
Geraldine Pannu DirectorPCSAProcessa PharmaceuticalsBuy$5,253 2,072 shares at $2.54 +1786% to stakeTraded Mar 31 Filed Apr 1
-
Patrick Lin Chief Business - Strategy OffPCSAProcessa PharmaceuticalsBuy$4,064 1,603 shares at $2.54 +91% to stakeTraded Mar 31 Filed Apr 1
-
Wendy Guy Chief Administrative OfficerPCSAProcessa PharmaceuticalsBuy$4,700 1,854 shares at $2.54 +148% to stakeTraded Mar 31 Filed Apr 1
-
Sian Bigora Chief Development OfficerPCSAProcessa PharmaceuticalsBuy$5,341 2,107 shares at $2.54 +131% to stakeTraded Mar 31 Filed Apr 1
-
Khoso Baluch DirectorPCSAProcessa PharmaceuticalsBuy$5,752 2,269 shares at $2.54 +4052% to stakeTraded Mar 31 Filed Apr 1
About this data
- Officers, directors and anyone owning more than 10% of a company must report a trade in its stock on a Form 4 within two business days. We read each filing from SEC EDGAR and link to it on every row.
- Only open-market purchases and sales of common stock count here. Stock grants, option exercises, gifts and shares withheld or sold to pay taxes on vesting awards are not decisions to buy or sell, so they are left out.
- A planned sale was made under a Rule 10b5-1 trading plan, which the insider set up months in advance. Many executives sell this way on a schedule, so a planned sale says less than one made on the day.
- Values are shares times the price reported. When a filing amends an earlier one, the amended trades replace the originals. Related owners (a fund and its manager) who report the same trade separately are shown once.
- We cover the 4,839 US companies on our earnings calendar, with a year of history. The superinvestor notes count the featured 13F managers who added or cut the stock in their latest quarter.